Loading…

Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model

Summary Background Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compounds, such as palmitoylethanolamine, the role of CBR agonists on inflammatory skin diseases is not yet fully understood. This study was performed to investigate the effects of CBR agonists on skin...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2015-10, Vol.54 (10), p.e401-e408
Main Authors: Kim, Hyun Jong, Kim, Bongwoo, Park, Bu Man, Jeon, Jeong Eun, Lee, Sin Hee, Mann, Shivtaj, Ahn, Sung Ku, Hong, Seung-Phil, Jeong, Se Kyoo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Even with the widespread clinical use of cannabinoid receptor (CBR) stimulating compounds, such as palmitoylethanolamine, the role of CBR agonists on inflammatory skin diseases is not yet fully understood. This study was performed to investigate the effects of CBR agonists on skin inflammation, using acute and chronic inflammation animal models. Methods The effectiveness of the newly synthesized cannabinoid receptor 1 (CB1R) agonists was determined using in vitro assays. Markers for epidermal permeability barrier function and skin inflammation were measured, and histological assessments were performed for evaluation. Results Topical application of CB1R‐specific agonist significantly accelerated the recovery of epidermal permeability barrier function and showed anti‐inflammatory activity in both acute and chronic inflammation models. Histological assessments also confirmed the anti‐inflammatory effects, which is consistent with previous reports. Conclusions All of the results suggest that topical application of CB1R‐specific agonist can be beneficial for alleviating the inflammatory symptoms in chronic skin diseases, including atopic dermatitis.
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.12841